EP4705318A2 - Auf die niere gerichtete aav-kapside und verfahren zu deren verwendung - Google Patents

Auf die niere gerichtete aav-kapside und verfahren zu deren verwendung

Info

Publication number
EP4705318A2
EP4705318A2 EP24797862.0A EP24797862A EP4705318A2 EP 4705318 A2 EP4705318 A2 EP 4705318A2 EP 24797862 A EP24797862 A EP 24797862A EP 4705318 A2 EP4705318 A2 EP 4705318A2
Authority
EP
European Patent Office
Prior art keywords
kidney
aav
syndrome
renal
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24797862.0A
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Nakai
Taisuke FURUSHO
Masahiro HORIKAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of EP4705318A2 publication Critical patent/EP4705318A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24797862.0A 2023-04-27 2024-04-24 Auf die niere gerichtete aav-kapside und verfahren zu deren verwendung Pending EP4705318A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363462492P 2023-04-27 2023-04-27
PCT/US2024/026078 WO2024226664A2 (en) 2023-04-27 2024-04-24 Kidney-targeting aav capsids and methods of use thereof

Publications (1)

Publication Number Publication Date
EP4705318A2 true EP4705318A2 (de) 2026-03-11

Family

ID=93257445

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24797862.0A Pending EP4705318A2 (de) 2023-04-27 2024-04-24 Auf die niere gerichtete aav-kapside und verfahren zu deren verwendung

Country Status (4)

Country Link
EP (1) EP4705318A2 (de)
CN (1) CN121013858A (de)
AU (1) AU2024262827A1 (de)
WO (1) WO2024226664A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774853A1 (de) * 2018-03-30 2021-02-17 The Board of Trustees of the Leland Stanford Junior University Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector

Also Published As

Publication number Publication date
CN121013858A (zh) 2025-11-25
AU2024262827A1 (en) 2025-10-16
WO2024226664A3 (en) 2025-02-06
WO2024226664A2 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
KR102373765B1 (ko) 벡터 제조 및 유전자 전달을 위한 캡시드-결핍 ａａｖ 벡터, 조성물 및 방법
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
EP3737423B1 (de) Zusammensetzungen und verfahren zur behandlung von netzhauterkrankungen
WO2025019295A2 (en) Renal pelvic injection for drug delivery to the kidney
US12534741B2 (en) Compositions and methods for treatment of neurological disorders
WO2021092518A1 (en) Transgene cassettes, aav vectors and aav viral vectors for the expression of human codon-optimized slc6a1
JP2025518145A (ja) 修飾されたアデノ随伴ウイルスカプシドタンパク質及びその方法
EP4705318A2 (de) Auf die niere gerichtete aav-kapside und verfahren zu deren verwendung
WO2019219649A1 (en) Gene therapy vectors comprising s/mar sequences
WO2016037931A1 (en) Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases
US20240342314A1 (en) Slc13a5 gene therapy vectors and uses thereof
WO2023091997A1 (en) Rnai therapy for apbd and lafora disease
JP2023532806A (ja) 新規の筋肉特異的プロモーター
US20250082782A1 (en) Transgene cassettes designed to express the human codon-optimized gene fmr1
WO2025193938A1 (en) Delivery of type iv collagen alpha chain using a split intein dual aav vector
WO2025003704A2 (en) Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
CN118955653A (zh) 腺相关病毒衣壳蛋白的突变体、编码其的核酸及应用
HK40030486B (en) Compositions and methods for treating retinal disorders
HK40030486A (en) Compositions and methods for treating retinal disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251103

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR